Calcium Electroporation for the Treatment of Colorectal Cancer

Colorectal Cancer Stage IV Clinical Trial

Official title:

Calcium Electroporation for the Treatment of Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03542214
• Other study ID #: HGH-2017-026
• Status: Completed
• Phase: Phase 1
• Start date: April 24, 2018
• Est. completion date: January 1, 2021

Study information

• Verified date: February 2021
• Source: Zealand University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this phase I study 6 patients with inoperable colorectal cancer is treated with calcium electroporation to establish safety and efficacy of the treatment.

Description:

A total of 6 evaluable patients with inoperable colorectal cancer are expected to be included in the study and the time for inclusion of patients is estimated to be 1-2 years. All patients will have been offered the standard of care and all available alternatives before entering the protocol. Calcium electroporation will not be compared to other means of treatment.

All patients will be treated once, but in case of residual tumor tissue at follow-up, and if the investigator considers it safe, they will be offered re-treatment. A maximum of 3 treatments per patient will be conducted with an interval of minimum 4 weeks. The patients will be followed with regular examinations for 12 months, starting from first treatment day.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: January 1, 2021
• Est. primary completion date: October 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically verified colorectal tumor

• Conferred by multidisciplinary team (radiologists, surgeons and oncologists) discussing options possible for the patient, resulting in agreement that an endoscopic treatment with calcium electroporation should be offered to the patient.

• Treatment free interval of minimum 2 weeks.

• Thrombocytes = 50 billions/l, INR >1,2. Medical correction is allowed, e.g. correction of elevated INR by means of vitamin K.

• Performance status ECOG/WHO =2

• Both men and women who are sexually active must use safe contraception (contraceptive coil, deposit injection of gestagen, subdermal implantation, hormonal vaginal ring or transdermal patch.)

• Trial subject = 18 years.

• Trial subject must be able to understand the participants' information.

• Signed informed consent. The patients are considered participants in the study after signing of the informed consent.

Exclusion criteria:

• Coagulative disturbance that cannot be corrected

• Pregnancy or lactation (Pregnancy is ruled out in fertile women by an HCG test in a blood sample)

• Concurrent participation in other clinical trials that involve experimental drugs or participation in a clinical trial involving experimental drugs within 4 weeks prior to administration of the drug in this study.

• Treatment with bevacizumab within the last 4 weeks.

• Heavily inflamed colorectal mucus membrane with bleeding or ulcerations.

• Implanted colon stent

• Other clinical disease or previous treatments that make the investigator deem the patient unfit.

Related Conditions & MeSH terms

• Colorectal Cancer Stage IV
• Colorectal Neoplasms

Intervention

Combination Product:
• Calcium electroporation
Patients with inoperable colorectal cancer will be treated with calcium electroporation

Locations

Country	Name	City	State
Denmark	Zealand University Hospital	Roskilde

Sponsors (1)

Lead Sponsor	Collaborator
Zealand University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of the calcium electroporation procedure in colorectal cancer (registration of adverse events; CTCAE v4 will be used)	Safety will be assessed through registration of adverse events related to the treatment. Furthermore, CT scans and follow-up endoscopies are performed as a safety marker to exclude any perforations, bleeding or infections. CTCAE v4 will be used.	12 months
Secondary	Local response	Tumor biopsies will be analyzed regarding standard histology and immunologic infiltration (CD8/CD3 and PD-L1/PD1)	18 months
Secondary	Systemic respons to calcium electroporation in colorectal cancer.	Blood samples will be collected. Multiplex cytokine analyses and transcriptional analyses will be performed. Furthermore cell adhesion assay will be performed. Additionally circulating tumor DNA will be measured as a marker for the tumor burden	12 months
Secondary	Tumorregression	CT/MR scans are performed and analyzed according to RECIST-criteria	12 months